GB201309333D0 - Purine diones as WNT pathway modulators - Google Patents

Purine diones as WNT pathway modulators

Info

Publication number
GB201309333D0
GB201309333D0 GBGB1309333.1A GB201309333A GB201309333D0 GB 201309333 D0 GB201309333 D0 GB 201309333D0 GB 201309333 A GB201309333 A GB 201309333A GB 201309333 D0 GB201309333 D0 GB 201309333D0
Authority
GB
United Kingdom
Prior art keywords
diones
purine
wnt pathway
pathway modulators
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1309333.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Priority to GBGB1309333.1A priority Critical patent/GB201309333D0/en
Publication of GB201309333D0 publication Critical patent/GB201309333D0/en
Priority to CA2912757A priority patent/CA2912757C/en
Priority to BR112015029182-1A priority patent/BR112015029182B1/pt
Priority to EP14801575.3A priority patent/EP2999699B1/en
Priority to CN201910142080.7A priority patent/CN109776537B/zh
Priority to ES14801575T priority patent/ES2802923T3/es
Priority to KR1020157035961A priority patent/KR102062262B1/ko
Priority to DK14801575.3T priority patent/DK2999699T3/da
Priority to SG11201509593TA priority patent/SG11201509593TA/en
Priority to KR1020197038593A priority patent/KR102153989B1/ko
Priority to AU2014269134A priority patent/AU2014269134B2/en
Priority to CN201480041283.2A priority patent/CN105452248A/zh
Priority to JP2016515318A priority patent/JP6506742B2/ja
Priority to US14/893,172 priority patent/US9926320B2/en
Priority to PCT/SG2014/000217 priority patent/WO2014189466A1/en
Priority to US15/668,260 priority patent/US10472360B2/en
Priority to AU2017219132A priority patent/AU2017219132B2/en
Priority to US15/899,675 priority patent/US10526335B2/en
Priority to US16/716,268 priority patent/US10844063B2/en
Priority to US17/100,474 priority patent/US11555037B2/en
Priority to US18/077,921 priority patent/US12559495B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB1309333.1A 2013-05-23 2013-05-23 Purine diones as WNT pathway modulators Ceased GB201309333D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB1309333.1A GB201309333D0 (en) 2013-05-23 2013-05-23 Purine diones as WNT pathway modulators
PCT/SG2014/000217 WO2014189466A1 (en) 2013-05-23 2014-05-19 Purine diones as wnt pathway modulators
AU2014269134A AU2014269134B2 (en) 2013-05-23 2014-05-19 Purine diones as WNT pathway modulators
JP2016515318A JP6506742B2 (ja) 2013-05-23 2014-05-19 Ｗｎｔ経路モジュレーターとしてのプリンジオン
EP14801575.3A EP2999699B1 (en) 2013-05-23 2014-05-19 Purine diones as wnt pathway modulators
CN201910142080.7A CN109776537B (zh) 2013-05-23 2014-05-19 作为wnt通路调节剂的嘌呤二酮
ES14801575T ES2802923T3 (es) 2013-05-23 2014-05-19 Purina dionas como moduladores de la ruta de Wnt
KR1020157035961A KR102062262B1 (ko) 2013-05-23 2014-05-19 Wnt 경로 조절제로서의 퓨린 디온
DK14801575.3T DK2999699T3 (da) 2013-05-23 2014-05-19 Purindioner som wnt-vej-modulatorer
SG11201509593TA SG11201509593TA (en) 2013-05-23 2014-05-19 Purine diones as wnt pathway modulators
KR1020197038593A KR102153989B1 (ko) 2013-05-23 2014-05-19 Wnt 경로 조절제로서의 퓨린 디온
CA2912757A CA2912757C (en) 2013-05-23 2014-05-19 Purine diones as wnt pathway modulators
CN201480041283.2A CN105452248A (zh) 2013-05-23 2014-05-19 作为wnt通路调节剂的嘌呤二酮
BR112015029182-1A BR112015029182B1 (pt) 2013-05-23 2014-05-19 Composto para uso em modulação da rota wnt, composição farmacêutica e uso
US14/893,172 US9926320B2 (en) 2013-05-23 2014-05-19 Purine diones as Wnt pathway modulators
US15/668,260 US10472360B2 (en) 2013-05-23 2017-08-03 Purine diones as Wnt pathway modulators
AU2017219132A AU2017219132B2 (en) 2013-05-23 2017-08-28 Purine diones as WNT pathway modulators
US15/899,675 US10526335B2 (en) 2013-05-23 2018-02-20 Purine diones as Wnt pathway modulators
US16/716,268 US10844063B2 (en) 2013-05-23 2019-12-16 Purine diones as Wnt pathway modulators
US17/100,474 US11555037B2 (en) 2013-05-23 2020-11-20 Purine diones as Wnt pathway modulators
US18/077,921 US12559495B2 (en) 2013-05-23 2022-12-08 Purine diones as Wnt pathway modulators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1309333.1A GB201309333D0 (en) 2013-05-23 2013-05-23 Purine diones as WNT pathway modulators

Publications (1)

Publication Number Publication Date
GB201309333D0 true GB201309333D0 (en) 2013-07-10

Family

ID=48784655

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1309333.1A Ceased GB201309333D0 (en) 2013-05-23 2013-05-23 Purine diones as WNT pathway modulators

Country Status (13)

Country Link
US (6) US9926320B2 (https=)
EP (1) EP2999699B1 (https=)
JP (1) JP6506742B2 (https=)
KR (2) KR102062262B1 (https=)
CN (2) CN109776537B (https=)
AU (2) AU2014269134B2 (https=)
BR (1) BR112015029182B1 (https=)
CA (1) CA2912757C (https=)
DK (1) DK2999699T3 (https=)
ES (1) ES2802923T3 (https=)
GB (1) GB201309333D0 (https=)
SG (1) SG11201509593TA (https=)
WO (1) WO2014189466A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
GB201322334D0 (en) * 2013-12-17 2014-01-29 Agency Science Tech & Res Maleimide derivatives as modulators of WNT pathway
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
HUE049253T2 (hu) * 2014-09-19 2020-09-28 Lilly Co Eli A tranziens receptor potenciál A1 ion csatorna gátlása
CN105440034B (zh) * 2015-11-16 2017-08-15 山东罗欣药业集团股份有限公司 一种利格列汀及其中间体的制备方法
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN106632332B (zh) * 2016-09-26 2018-07-06 杭州新博思生物医药有限公司 一种伊曲茶碱的制备方法
CN111247148B (zh) * 2017-09-14 2022-12-20 新加坡科技研究局 Wnt通路调节剂
WO2019152465A1 (en) 2018-01-31 2019-08-08 Eli Lilly And Company Inhibiting the transient receptor potential a1 ion channel
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
US12534762B2 (en) 2018-09-28 2026-01-27 Children's Medical Center Corporation Treating atopic dermatitis by targeting the WNT pathway
CN114025764A (zh) * 2019-05-22 2022-02-08 新加坡科技研究局 药物组合
CN114072131B (zh) * 2019-05-22 2024-03-19 新加坡科技研究局 口服制剂、其制备方法及其用途
US12365686B2 (en) * 2019-07-08 2025-07-22 Jiangsu Kanion Pharmaceutical Co., Ltd. Compound as porcupine inhibitor and use thereof
CN115279377A (zh) * 2020-01-08 2022-11-01 新加坡科技研究局 联合疗法
BR112023025403A2 (pt) 2021-06-25 2024-02-20 Korea Res Inst Chemical Tech Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
KR20240073960A (ko) * 2021-10-29 2024-05-27 지앙수 카니온 파마수티컬 씨오., 엘티디. 5-치환된 피리딘-2(1h)-케톤계 화합물 및 이의 용도
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
CN120737092B (zh) * 2025-09-05 2025-11-14 利诚检测认证集团股份有限公司 别嘌醇半抗原及其制备方法、人工抗原、抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
AU2006327181A1 (en) 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
ES2609912T3 (es) * 2007-06-22 2017-04-25 Hydra Biosciences, Inc. Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1
CN101909630A (zh) * 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20120108614A1 (en) 2008-05-14 2012-05-03 Chong Jayhong A Compounds and compositions for treating chemical warfare agent-induced injuries
US20120046305A1 (en) 2008-09-24 2012-02-23 Moran Magdalene M Methods and compositions for treating respiratory disorders
TW201026700A (en) * 2008-12-22 2010-07-16 Hydra Biosciences Inc Compositions useful for treating disorders related to TRPA1
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
PE20140234A1 (es) * 2010-12-20 2014-03-08 Glenmark Phamaceuticals S A Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1
CA2836856A1 (en) * 2011-06-13 2012-12-20 Glenmark Pharmaceuticals, S.A. Treatment of respiratory disorders using trpa1 antagonists
JP5659098B2 (ja) * 2011-07-19 2015-01-28 株式会社東芝 半導体装置の製造方法
US20140148423A1 (en) * 2011-07-25 2014-05-29 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a steroid
AR087501A1 (es) * 2011-08-09 2014-03-26 Hydra Biosciences Inc Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1
IN2014CN02646A (https=) * 2011-09-14 2015-08-07 Samumed Llc
CN107674071B (zh) 2012-05-11 2021-12-31 同步制药公司 作为隐花色素调节剂的含有咔唑的磺酰胺类
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators

Also Published As

Publication number Publication date
JP2016519165A (ja) 2016-06-30
US11555037B2 (en) 2023-01-17
BR112015029182A8 (pt) 2020-03-17
DK2999699T3 (da) 2020-07-13
US20230174533A1 (en) 2023-06-08
SG11201509593TA (en) 2015-12-30
AU2014269134A1 (en) 2015-12-10
US10472360B2 (en) 2019-11-12
BR112015029182A2 (pt) 2017-07-25
US10844063B2 (en) 2020-11-24
KR102062262B1 (ko) 2020-01-03
US10526335B2 (en) 2020-01-07
US20160090386A1 (en) 2016-03-31
AU2014269134B2 (en) 2017-06-15
US12559495B2 (en) 2026-02-24
US9926320B2 (en) 2018-03-27
AU2017219132B2 (en) 2019-04-18
US20180170932A1 (en) 2018-06-21
EP2999699A4 (en) 2016-10-26
WO2014189466A1 (en) 2014-11-27
JP6506742B2 (ja) 2019-04-24
US20210155623A1 (en) 2021-05-27
BR112015029182B1 (pt) 2023-10-03
ES2802923T3 (es) 2021-01-21
CN105452248A (zh) 2016-03-30
EP2999699B1 (en) 2020-04-29
CN109776537A (zh) 2019-05-21
US20200190086A1 (en) 2020-06-18
CN109776537B (zh) 2021-12-14
EP2999699A1 (en) 2016-03-30
KR20200000504A (ko) 2020-01-02
KR102153989B1 (ko) 2020-09-09
AU2017219132A1 (en) 2017-09-14
KR20160029024A (ko) 2016-03-14
CA2912757C (en) 2021-11-30
CA2912757A1 (en) 2014-11-27
US20170334912A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
SG11201509593TA (en) Purine diones as wnt pathway modulators
GB201305109D0 (en) Inks
SG11201604839XA (en) Wnt pathway modulators
GB201300276D0 (en) Photo-detector
GB201307564D0 (en) WNT pathway modulator
PL2860446T3 (pl) Wskaźnik świetlny
GB2520034B (en) Brake light
GB201322919D0 (en) Brake arrangement
GB2521592B (en) Axles
GB201321601D0 (en) Modulator
GB201311130D0 (en) Greensleeves I
GB201306901D0 (en) Combination
GB201312727D0 (en) Modulators
TWM476059U (en) Hub
GB201318298D0 (en) Modulators
GB201317988D0 (en) Modulators
GB201304473D0 (en) Modulators
GB201319626D0 (en) frb ecolock
AU351718S (en) Light
AU351717S (en) Light
AU349787S (en) Light
GB201302797D0 (en) Hub
GB201302671D0 (en) Hub
IL230049A0 (en) ink
AU353910S (en) Confectionery

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)